In a nutshell The aim of this study was to evaluate the safety and effectiveness of combining androgen deprivation therapy (ADT) with docetaxel (Taxotere) plus prednisone (Deltasone) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The study found that this combination improved the outcomes of these...
Read MoreCurrent stage -Stage IV Posts on Medivizor
Cetuximab combined with chemotherapy improves the outcomes of patients with advanced colorectal cancer
In a nutshell This study investigated the effectiveness of cetuximab (Erbitux) in combination with chemotherapy for the treatment of advanced colorectal cancer (CRC). Researchers suggested that this combined treatment improves the outcomes of patients with CRC. Some background CRC is one of the most common cancers worldwide. Around 15 to 25% of...
Read MoreCan oral relugolix be used as androgen-deprivation therapy in advanced prostate cancer?
In a nutshell The study looked at whether oral relugolix (Orgovyx, Relumina) could be used to suppress testosterone in men with advanced prostate cancer compared to leuprolide (Lupron). This study showed that relugolix was associated with more rapid and effective suppression of testosterone levels when compared...
Read MoreTucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain
In a nutshell This study looked at treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases (BM) with tucatinib (Tukysa) plus trastuzumab (Herceptin) and capecitabine (Xeloda). This study found that this treatment reduces the risk of cancer worsening in these...
Read MoreBevacizumab combined with chemotherapy improves the outcomes of elderly patients with advanced colorectal cancer
In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) combined with chemotherapy in elderly patients with advanced colorectal cancer. Researchers suggested that this therapy might be associated with improved outcomes in fit older patients. Some background Colorectal cancer is the third most common cancer...
Read MoreFOLFOXIRI plus bevacizumab improve the outcomes of patients with advanced colorectal cancer
In a nutshell This study compared two different types of chemotherapy for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) is associated with better outcomes in these patients. Some background Colorectal cancer is the third most common cancer...
Read MoreHow long should hormonal treatment be given to patients with locally advanced prostate cancer?
In a nutshell This study compared 6-month and 18-month courses of hormonal anti-androgen treatment and radiotherapy (RT) in patients with locally advanced prostate cancer (LAPC). The results showed that 18-month treatment was most effective, especially when used with high dose brachytherapy RT. Some background Androgens (such as testosterone) are...
Read MoreWhat are the long-term effects of treatment with a biological drug versus chemotherapy for patients with advanced non-small cell lung carcinoma?
In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...
Read MoreCytoreductive surgery improves survival in patients with advanced colorectal cancer
In a nutshell This study investigated the effectiveness of cytoreductive surgery (CRS) in patients with colorectal cancer spread to the peritoneum (inner lining of the abdominal cavity). Researchers suggested that CRS is associated with improved survival in these patients. Some background Colorectal cancer is the third most common cancer worldwide. A...
Read MoreQuality of life in patients with advanced prostate cancer after apalutamide treatment
In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...
Read MoreEvaluating the order of hormone therapy drugs for patients with prostate cancer
In a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...
Read MoreAbiraterone acetate and prednisone in patients with metastatic, castration‑sensitive prostate cancer
In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...
Read More